Moreover, DGG-100629 reduced the proliferation of gefitinib-resistant lung cancer cells isolated from patients who expressed high levels of NFATc1 and DDIAS, suggesting that blocking DDIAS transcription is a unique approach for the treatment of gefitinib-resistant lung cancer. The gene discussed is NFATC1; the disease is lung cancer.